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DOI 10.1186/s13058-017-0850-5RESEARCH ARTICLE Open AccessAge-related terminal duct lobular unit
involution in benign tissues from Chinese
breast cancer patients with luminal and
triple-negative tumors
Changyuan Guo1†, Hyuna Sung2†, Shan Zheng1, Jennifer Guida2, Erni Li1, Jing Li1, Nan Hu2, Joseph Deng2,
Jonine D. Figueroa2,3, Mark E. Sherman2,4, Gretchen L. Gierach2, Ning Lu1† and Xiaohong R. Yang2*†Abstract
Background: Terminal duct lobular unit (TDLU) involution is a physiological process of breast tissue aging
characterized by a reduction in the epithelial component. In studies of women with benign breast disease,
researchers have found that age-matched women with lower levels of TDLU involution are at increased risk of
developing breast cancer. We previously showed that breast cancer cases with core basal phenotype (CBP; estrogen
receptor negative [ER−], progesterone receptor-negative [PR−], human epidermal growth factor receptor 2-negative
[HER2−], cytokeratins (CK 5 or CK5/6)-positive [CK5/6+] and/or epidermal growth factor receptor-positive [EGFR+])
tumors had significantly reduced TDLU involution compared with cases with luminal A (ER+ and/or PR+, HER2−,
CK5/6−, EGFR−) tumors from a population-based case-control study in Poland. We evaluated the association of
TDLU involution with tumor subtypes in an independent population of women in China, where the breast cancer
incidence rate, prevalence of known risk factors, and mammographic breast density are thought to be markedly
different from those of Polish women.
Methods: We performed morphometric assessment of TDLUs by using three reproducible semiquantitative
measures that inversely correlate with TDLU involution (TDLU count/100 mm2, TDLU span in micrometer, and
acini count/TDLU) by examining benign tissue blocks from 254 age-matched luminal A and 250 triple-negative
(TN; ER−, PR−, HER2−, including 125 CBP) breast cancer cases treated in a tertiary hospital in Beijing, China.
Results: Overall, we found that TN and particularly CBP cases tended to have greater TDLU measures (less involution)
than luminal A cases in logistic regression models accounting for age, body mass index, parity, and tumor grade. The
strongest association was observed for tertiles of acini count among younger women (aged <50 years) (CBP vs. luminal
A; ORtrend 2.11, 95% CI 1.22–3.67, P = 0.008).
Conclusions: These data extend previous findings that TN/CBP breast cancers are associated with reduced TDLU
involution in surrounding breast parenchyma compared with luminal A cases among Chinese women, providing
further support for differences in the pathogenesis of these tumor subtypes.
Keywords: Terminal ductal lobular unit (TDLU) involution, Breast cancer, Tumor subtype, Luminal tumor, Triple-negative
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Age-related terminal duct lobular unit (TDLU) involu-
tion is a physiological process of breast tissue aging by
which the epithelial components of TDLUs atrophy and
disappear. Importantly, TDLUs also represent the pri-
mary anatomical sources of breast cancers and their pre-
cursors [1]. In studies of women with benign breast
disease, women with lesser degrees of TDLU involution
had increased risk of subsequent breast cancer [2–4],
and incorporation of involution in risk prediction has re-
sulted in improved risk prediction [5]. Further, because
individual variations in TDLU involution are also associ-
ated with breast cancer risk factors including age, meno-
pausal status, parity, menopausal hormone therapy, and
mammographic breast density (MD) [6–8], TDLU invo-
lution may represent an important marker of risk and an
intermediate endpoint of breast cancer.
Breast cancer can be classified into different subtypes
based on immunohistochemical expression of estrogen re-
ceptor (ER), progesterone receptor (PR), human epidermal
growth factor receptor 2 (HER2), cytokeratins (CK5 or
CK5/6), and epidermal growth factor receptor (EGFR).
Among these subtypes, triple-negative (TN; ER−, PR−,
HER2−) subtypes have been associated with features that
contrast with those of luminal ER+ breast cancer (younger
age at onset, higher prevalence of BRAC1 germline muta-
tions, and African American race) [9], distinct risk factors
(greater and earlier parity, lack of breastfeeding, higher
prevalence of positive family history of breast cancer)
[10, 11], and worse prognosis [12]. Particularly, the core
basal phenotype (CBP; ER−, PR−, HER2−, CK5/6+, and/or
EGFR+) has been considered as displaying the most distinct-
ive features compared with the luminal A subtype [12, 13].
In a previous study of Polish patients with breast can-
cer younger than age 55 years (232 luminal A and 49
CBP), we showed that TDLUs associated with CBP
tumors had significantly reduced TDLU involution com-
pared with parenchyma associated with luminal A tumors
(ER+ and/or PR+, HER2−) [14]. Specifically, compared with
luminal A tumors, CBP tumors tended to have a greater
average number of acini per TDLU and a larger average
TDLU span. The goal of the present study was to test the
hypothesis that TDLU involution is reduced in breast
parenchyma associated with CBP compared with lu-
minal A tumors among Asian women, a group with lower
reported incidence rates of breast cancer and generally
smaller, more mammographically dense breasts than
Western women [15].
Methods
Study population
Data and biologic specimens for the present analysis
were collected from female patients with invasive breast
cancer who had surgeries at Cancer Hospital, ChineseAcademy of Medical Sciences (CHCAMS), Beijing,
China, between 2009 and 2012. Eligible subjects in-
cluded those who had a confirmed breast cancer diagno-
sis, had complete pathologic data, and had not received
neoadjuvant therapies prior to surgeries. Breast cancer
risk factors were extracted from medical records, which
included age at diagnosis, body mass index (BMI), age at
menarche, number of children, breastfeeding (yes or no),
and first-degree family history of breast cancer. Patho-
logic data were retrieved from pathology reports, includ-
ing tumor size; tumor grade; axillary lymph node status;
and marker expression levels of ER, PR, HER2, CK5
(or CK 5/6), and EGFR. The status of ER, PR, CK5
(or CK 5/6), and EGFR expression in tumors was deter-
mined by immunohistochemistry (IHC), and >1% staining
was considered as positive. HER2 expression was deter-
mined by IHC and fluorescence in situ hybridization
(FISH), and either an IHC score of 3+ or a FISH-positive
test result was defined as HER2+. To avoid misclassifica-
tion, we excluded all HER2+ cases without FISH data.
Basal marker (CK5 (or CK 5/6) and EGFR) information
was available for women diagnosed between 2011 and
2012, and we identified all CBP cases (ER−, PR−, HER2−,
CK5/6+, and/or EGFR+) in these two years. To increase
power, we also identified TN cases defined by ER, PR, and
HER2 (ER−, PR−, HER2−) from earlier years, resulting in a
study set including a total of 328 TN/CBP cases. Given
the aim of comparing TDLU involution associated with
TN/CBP and luminal A breast cancers, we restricted the
analysis to these two subtypes. We then performed
10-year age frequency matching to select luminal A cases
(n = 328) that were defined as ER+ and/or PR+, HER2−,
and negative for both basal markers. Tissue sections pre-
pared from grossly benign breast tissue were stained with
hematoxylin and eosin (H&E) and scanned to create
digital image files. Cases with low-quality images (n = 11)
or benign changes throughout the section (duct dila-
tion, metaplasia, hyperplasia; n = 26), microscopic evi-
dence of ductal carcinoma in situ (n = 32), or invasive
cancer (n = 97) were excluded, resulting in 504 cases in
the final analysis (254 luminal A and 250 TN/CBP cases
[125 CBP]). The project was approved by the CHCAMS
Ethics Committee and exempted from review by the
Office for Human Research Protections at the National
Institutes of Health because it did not involve interaction
with human subjects and/or use of subjects’ personal
identifying information (exempt number 11751).
TDLU assessment
Grossly normal breast tissue blocks were retrieved, and
H&E-stained tissue sections were scanned (Aperio Scan-
Scope; Aperio Technologies, Vista, CA, USA) and loaded
into Digital Image Hub software for review (SlidePath/
Leica Microsystems, Dublin, Ireland). The lasso tool in
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measure total tissue area in square millimeters per section.
TDLU involution was assessed using three semiquantita-
tive measures with previously demonstrated reproducibil-
ity [4, 6]: TDLU count per unit area (count/100 mm2),
TDLU span (measured with an electronic ruler in micro-
meters), and acini count per TDLU, all showing inverse
correlations with TDLU involution [6]. Among women
with observable normal TDLUs, up to ten sequential
TDLUs were evaluated for acini count per TDLU
(categories: 1 = 2–10, 2 = 11–20, 3 = 21–30, 4 = 31–50,
5 = 51–100, and 6 = >100) and TDLU span (maximum
diameter of a TDLU), as previously described [6]. Both
maximal and median values of acini count/TDLU and
TDLU span were used as summary measures for each pa-
tient. All morphologic measurements were performed by
a single trained cytotechnologist (R. Cora). To assess
intrawoman concordance in TDLU involution measures,
we evaluated two different benign sections within a single
case that were available for 100 cases. Within-woman
Spearman’s correlation coefficients (r2) were 0.58 for
TDLU count, 0.65 for median acini count/TDLU, and
0.69 for median TDLU span.
Statistical analysis
The associations between breast cancer risk factors and
TDLU involution measures were assessed using ordinal
logistic regression models with tertiles of each TDLU in-
volution measure as the outcome variable and breast can-
cer risk factors and clinical characteristics as explanatory
variables. The associations between breast tumor subtype
and TDLU involution measures were assessed using logis-
tic regression with tumor subtype as the outcome variable
(TN/CBP or CBP vs. luminal A) and TDLU involution
measures as explanatory variables (comparing the second
and third tertiles with the first tertile).
Trend P values, ORs, and 95% CIs were estimated, treat-
ing tertiles of TDLU involution measures as ordinal vari-
ables. Adjustment variables included potential confounders
and/or tumor characteristics that were significantly associ-
ated with both TDLU measures and tumor subtypes
(Table 1 and Additional file 1: Table S1): age (5-year inter-
vals), BMI (<23, 23–24.9, 25–29.9, or 30+ kg/m2), parity
(nulliparous vs. parous), and tumor grade (well, moder-
ately, or poorly differentiated). To evaluate potential effect
modification by age, we also performed stratified analysis
by age (<50 vs. 50+ years), with cutpoints for tertiles deter-
mined based on distributions in each age group. All
analyses were performed using SAS version 9.3 software
(SAS Institute Inc., Cary, NC, USA).
Results
In this study population including 504 breast cancer
cases (254 luminal A and 250 TN/CBP), the mean (SD)age at diagnosis was 50.4 (9.4) years, and mean (SD)
BMI was 25.1 (3.7) kg/m2. The majority of women did
not report a family history of breast cancer (95%), had
one (62.1%) or more than one (34.1%) child, and had
breastfed their children (93.8%). Table 1 shows the dis-
tribution of TDLU involution measures by breast cancer
risk factors and tumor characteristics. In the multivariable
model including all examined risk and clinical factors, all
three TDLU involution measures were inversely associated
with age. Parity, breastfeeding, tumor subtype, and tumor
grade were associated with some TDLU involution mea-
sures. Specifically, subjects who were parous (particularly
having one child) were more likely to have a greater num-
ber of TDLUs and acini per TDLU than nulliparous
women. Among parous women, women who had breast-
fed had larger TDLUs and a greater number of acini per
TDLU than women who had never breastfed. Subjects
with TN/CBP or higher-grade tumors also tended to have
larger TDLUs and a greater number of acini per TDLU.
Table 2 shows the association between tumor subtype
and measures of TDLU involution among all cases after
accounting for potential confounders such as age, parity,
BMI, and tumor grade. TN/CBP cases, in particular CBP
cases, were more likely to have greater TDLU count, lar-
ger TDLU span, and greater number of acini per TDLU
(all related to less involution) than luminal A cases, al-
though most comparisons were not statistically significant.
The strongest association was observed for maximum
number of acini per TDLU (ORtrend 1.42, 95% CI 1.01–
2.01, Ptrend 0.045 for TN/CBP; ORtrend 1.69, 95% CI 1.12–
2.55, Ptrend 0.012 for CBP vs. luminal A cases). When ana-
lyzing younger and older women separately (Table 3), we
found that the association of reduced TDLU involution and
CBP was observed only among women younger than age
50 years, with the strongest effect found for maximum
category of acini per TDLU when we compared CBP
and luminal A cases (ORT3 vs. T1 4.39, 95% CI 1.45–13.23,
P = 0.009; ORtrend 2.11, 95% CI 1.22–3.67, Ptrend = 0.008).
Among older women, statistically significant associations
between measures of TDLU involution and tumor subtype
were not apparent. Similar but slightly weakened associa-
tions were observed when we used median values as
summary measures for TDLU span and acini count/
TDLU (Additional file 1: Table S2).
Discussion
In this study, we demonstrated that some measures of
TDLU involution are reduced in breast parenchyma asso-
ciated with TN/CBP as compared with luminal A cancers
among Chinese women, particularly those younger than
age 50 years, which is generally similar to our previously
reported finding among Polish women [14]. Our finding
adds to the accumulating evidence that the etiology and
pathogenesis of these breast tumor subtypes differ.
Table 1 Distributions in measures of terminal duct lobular unit involution by breast cancer risk factors and tumor characteristics
among Chinese patients with breast cancer
Overall (n = 504) Measures of TDLU involution
Count/100 mm2 Maximum span (μm) Maximum category of acini count/TDLUa
Subjects (n) % Median (IQR) Median (IQR) 1–3 4–6
Number % Number %
Age
All, mean (SD) 50.4 9.4
20–39 years 48 9.5 30.8 (15.7–48.0) 924 (759.5–1308.5) 14 5.0 34 15.3
40–49 years 204 40.5 29.9 (17.4–44.6) 934.5 (712–1154) 71 25.2 133 59.9
50–59 years 176 34.9 12.3 (7.0–22.9) 674 (532.5–847.5) 131 46.5 45 20.3
60–79 years 76 15.1 8.7 (3.7–15.2) 559 (391.5–740) 66 23.4 10 4.5
P valueb <0.0001 <0.0001 <0.0001
Body mass index
All, mean (SD) 25.1 3.7
< 23 kg/m2 155 30.9 19.2 (8.7–32.6) 773 (599–1075) 84 30.1 71 32.0
23–24.9 kg/m2 121 24.2 19.0 (10.2–37.2) 747 (565–964) 67 24.0 54 24.3
25–29.9 kg/m2 180 35.9 18.8 (9.1–36.8) 813.5 (613–1025) 98 35.1 82 36.9
30+ kg/m2 45 9.0 14.3 (8.3–27.2) 784 (566–946) 30 10.8 15 6.8
P valueb 0.73 0.50 0.92
Family history of breast cancer
No 470 95.0 18.3 (8.7–34.8) 775 (591–1023) 265 95.0 205 94.9
Yes 25 5.1 17.1 (10.7–30.0) 751 (461–979) 14 5.0 11 5.1
P valueb 0.76 0.12 0.55
Age at menarche
< 12 years 122 25.4 18.9 (10.8–38.6) 789.5 (603–1023) 68 24.7 54 26.2
12–13 years 215 44.7 19.7 (8.5–36.3) 796 (611–1080) 112 40.7 103 50.0
14+ years 144 29.9 15.4 (7.2–28.6) 713 (536.5–954) 95 34.6 49 23.8
P valueb 0.99 0.99 0.94
Parity/number of children
Nulliparous 18 3.9 10.9 (4.6–36.6) 818 (482–1155) 11 4.2 7 3.4
One child 290 62.1 20.0 (11.1–36.3) 804.5 (612–1075) 147 56.3 143 69.4
More than one child 159 34.1 14.7 (7.3–33.8) 754 (547–955) 103 39.5 56 27.2
P valueb 0.02 0.14 0.06
Breastfeedingc
No 19 6.2 15.4 (7.8–28.1) 565 (468–887) 14 8.1 5 3.8
Yes 286 93.8 18.3 (9.0–34.2) 790.5 (621–1025) 158 91.9 128 96.2
P valueb 0.48 0.05 0.08
Tumor subtype
Luminal A 254 50.4 17.4 (8.3–32.8) 764.5 (600–992) 152 53.9 102 46.0
Triple-negative/core
basal phenotype
250 49.6 19.5 (10.0–37.8) 803 (588–1043) 130 46.1 120 54.1
P valueb 0.45 0.10 0.03
Tumor size
≤ 2 cm 277 56.4 18.3 (8.3–34.2) 777 (583–998) 160 58.4 117 53.9
> 2 cm 214 43.6 20.0 (10.1–35.8) 794 (606–1034) 114 41.6 100 46.1
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Table 1 Distributions in measures of terminal duct lobular unit involution by breast cancer risk factors and tumor characteristics
among Chinese patients with breast cancer (Continued)
P valueb 0.71 0.76 0.19
Lymph node invasion
Negative 286 58.7 17.6 (9.4–34.9) 780.5 (566–989) 160 58.6 126 58.9
Positive 201 41.3 19.8 (8.4–34.1) 781 (604–1075) 113 41.4 88 41.1
P valueb 0.86 0.27 0.81
Grade
Well differentiated 47 10.2 20.3 (8.3–40.0) 887 (644–1198) 26 10.0 21 10.5
Moderately differentiated 201 43.5 17.5 (9.4–36.0) 770 (599–979) 113 43.3 88 43.8
Poorly differentiated 214 46.3 18.7 (9.2–33.0) 774.5 (566–1025) 122 46.7 92 45.8
P valueb 0.32 0.01 0.07
TDLU Terminal duct lobular unit
aCategories for acini count/TDLU: 1 = 2–10, 2 = 11–20, 3 = 21–30, 4 = 31–50, 5 = 51–100, and 6 = >100
bP values were obtained from ordinal logistic regression models using tertiles of TDLU involution measures as the outcome variable and age (5-year intervals),
body mass index (<23, 23–24.9, 25–29.9, or 30+ kg/m2), parity (nulliparous, one child, and more than one child), tumor subtype (luminal A and triple-negative/core
basal phenotype), and grade (well, moderately, or poorly differentiated) as explanatory variables
cParous women only
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a number of breast cancer risk factors, including age,
BMI, parity, family history of breast cancer, menopausal
hormone therapy, and MD, in healthy women or women
with benign breast disease [6–8]. In this study of Chin-
ese patients with breast cancer, we observed associations
of age, parity, and breastfeeding with TDLU involution
measures similar to those shown in previous studies. To-
gether, these findings suggest that measures of TDLU in-
volution may reflect lifetime exposures to breast cancer
risk factors and therefore may provide etiologic clues to
breast tumor subtypes. For example, parity is known to
protect ER+ breast cancer but may increase the risk of
TN/CBP cancer [13, 16]. Parity has consistently been
shown to be associated with less TDLU involution in a
number of studies [4, 6, 14] and may explain the in-
crease in risk for CBP breast cancer, whereas the parity-
related protection for ER+ cancer may be mediated
through a different mechanism that is independent of
TDLU involution. Similarly, breastfeeding was associated
with more TDLU involution among premenopausal
women but with less involution among postmenopausal
women [6]. Studies of African Americans showed that
long-term breastfeeding had a stronger protective effect
for TN than for luminal cases [16], suggesting that
TDLU involution may partially mediate the protective
effect of breastfeeding, particularly among younger
women. Previous studies also associated having a posi-
tive family history of breast cancer with less TDLU invo-
lution [6], consistent with the observation that family
history is more prevalent in cases with CBP tumors.
These results, together with previously reported subtype
differences in molecular mechanisms related to breast
cancer risk factors such as parity [17], suggest that
breast cancer risk factors may influence molecularpathways differently in different subtypes with distinct
biological characteristics of at-risk tissue, which is mani-
fested as TDLU involution.
According to the “breast tissue aging” concept pro-
posed by Pike et al. [18], breast epithelium and stroma
should be influenced by similar factors, such as age and
parity [19]. Consistent with this notion, MD and TDLU
involution have been shown to be correlated: Women
with higher MD are likely to show lesser degrees of
TDLU involution [7, 20]. Although correlated, reduced
TDLU involution and elevated MD have also been
shown to be independently associated with increased
breast cancer risk [8]. However, MD has not consistently
been associated with specific breast cancer subtypes
[21]. Our finding of an involution-subtype association
suggests that TDLU involution, which reflects changes
that are specific in breast epithelium, may better capture
the subtype-specific carcinogenic process than MD. Of
note, the histologic feature that is more strongly corre-
lated with MD is TDLU span [7], whereas data from this
study and the previous analysis of Polish women re-
vealed that subtype was most closely linked to acini per
TDLU. This is consistent with the histologic observation
that acini and epithelial content may decline even when
the boundaries of TDLUs remain largely unchanged.
Among the three metrics of TDLU involution, TDLU
span and acini count per TDLU are usually highly corre-
lated, whereas they show only weak correlations with
TDLU count [6, 7]. Together with the various associations
of breast cancer risk factors with specific TDLU metrics
[6], these observations suggest that different involution
variables may reflect different biological mechanisms or
stages of TDLU involution and that acini count per TDLU
measure may be more relevant to capturing tumor
subtype-specific pathology. Alternatively, the differences
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less, the associations with tumor subtype for all three
TDLU metrics showed the same directions in both overall
and stratified analyses, suggesting that the TDLU
involution-subtype association is not specific to certain in-
volution measurements.
Studying interrelationships between histologic and
radiologic measures of breast tissue composition in
Chinese women is an area requiring further exploration. In
addition, we found that the association of acini per TDLU
with tumor subtype was stronger when using maximal ra-
ther than median acinar value as the summary measure-
ment for each subject, despite the high correlation between
the two metrics (Spearman’s r2 = 0.83), suggesting that the
maximal number of acini count per TDLU may provide
important information in terms of subtype associations.
Our study is the first study to describe features of
TDLU involution among Asian women using three stan-
dardized quantitative measures including TDLU count
per unit area, which was not previously assessed in the
Polish study. In Polish cases [14], we restricted the ana-
lysis to younger women (aged <55 years) and women
with observed TDLUs. In the present study, we extended
the evaluation to a broader age range because the intact
TDLU structure was persistent even among very old
women in this Chinese population. The magnitude of as-
sociation between acini count and CBP tumor among
younger (aged <50 years) Chinese cases (ORT3 vs. T1 4.39)
was similar to what was observed among Polish cases
(ORT3 vs. T1 4.44). Given the considerable differences in
the prevalence of breast cancer risk factors such as BMI
and MD in Chinese and Western women, future research
is needed to investigate whether the natural history of
TDLU involution is different in diverse populations.
Several limitations of our study should be noted. First,
our study is limited by the relatively small sample size, es-
pecially in stratified analyses by age and in the analysis re-
stricted to CBP tumors. Second, we defined the luminal A
subtype based on ER, PR, HER2, and basal markers only,
and therefore a number of high-grade luminal tumors were
included. Future studies with more accurate tumor subtype
information are needed to better quantify the association.
Nevertheless, the replication of a TDLU involution-subtype
association in an independent population highlights the
importance of studying TDLU involution as a possible
intermediate endpoint in breast cancer carcinogenesis. Be-
cause of the cross-sectional design of our study, we were
not able to evaluate whether concurrent TDLU involution
features associated with tumor subtype preceded tumor
development or occurred later during cancer progression.
However, our previous study among cancer cases indicated
high correlations between TDLU metrics (e.g., acini count
and diameter) within an individual, regardless of tumor
proximity (proximal vs. distant normal to tumor) [14]. Inaddition, researchers in a study of women with benign
breast disease also reported a high level of agreement in in-
volution measures across multiple biopsy specimens within
a woman [2]. These observations suggest that the observed
involution-subtype association is less likely to be driven by
tumor progression. Nevertheless, more detailed studies
with prospective designs are needed to definitively assess
the temporal and spatial relationships between TDLU in-
volution and tumor subtypes. Finally, information on some
established breast cancer risk factors that may potentially
influence both TDLU involution and tumor subtypes, such
as menopausal hormone therapy, was not collected in our
study. However, given the low menopausal hormone
therapy prevalence among Chinese women [22] and low
population-attributable risk of breast cancer due to
menopausal hormone therapy in Asian women in general
[23, 24], it is unlikely that the lack of information on
menopausal hormone therapy had a significant impact on
the association between TDLU involution and tumor sub-
type in postmenopausal women.
In summary, we have confirmed the previously observed
association between greater acini count per TDLU
(reflecting reduced TDLU involution) and the TN subtype
in an independent Asian population. Our results further
support the different etiology and pathogenesis of breast
cancer subtypes and highlight the importance of investigat-
ing TDLU involution as a possible intermediate endpoint
in breast cancer carcinogenesis among diverse populations.
Further, future efforts to combine TDLU involution met-
rics with follow-up data may lead to important transla-
tional findings on local recurrence and treatment efficacy.
Conclusions
In this study of Chinese women, a group with typically
lower breast cancer incidence rates and denser breasts than
Western women, we showed again that TN/CBP cases had
a significantly higher acini count per TDLU than luminal
cases. Our findings strengthen and extend the previous ob-
servation that involution is associated with breast cancer
subtype, which may have implications for understanding
the pathogenesis of breast cancer. Future investigations in
large studies and diverse populations are needed to further
explore ethnic differences in TDLU involution in relation
to etiologic factors and tumor characteristics.
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